Direct answer: Start with the approved indication and your medical history, then compare expected benefit, safety, tolerability, product form, and reliable access. SURMOUNT-5 found greater average weight loss with tirzepatide, but that single result does not make it the right option for everyone.
Dr. Anita Petruzzelli, MD, OB-GYN
Use a clinical decision, not a winner label
Online comparisons often ask which drug is better. A prescriber needs a narrower question: better for which diagnosis, goal, risk profile, previous response, and access situation? Semaglutide and tirzepatide are active ingredients used in specific products. The product name and approved use matter because labels, doses, formulations, and evidence populations differ.
For chronic weight management, the familiar comparison is Wegovy versus Zepbound. Ozempic and Mounjaro have type 2 diabetes indications, so substituting those names can blur what was actually studied or prescribed. Compounded products are also not FDA-approved equivalents of the branded drugs and are not covered by the same premarket review.
Match the treatment to the goal and indication
| Question | Why it can change the discussion |
|---|---|
| Is the primary goal chronic weight management? | Both Wegovy and Zepbound have FDA weight-management indications for eligible patients. |
| Is established cardiovascular disease present? | Wegovy has an indication to reduce major cardiovascular events in certain adults with cardiovascular disease and obesity or overweight. |
| Is moderate-to-severe obstructive sleep apnea present with obesity? | Zepbound has an indication for this population. |
| Is noncirrhotic MASH with F2 to F3 fibrosis present? | Wegovy has an accelerated-approval indication with specific eligibility and continued-confirmation requirements. |
| Is type 2 diabetes the treatment focus? | The prescriber should use diabetes-specific products, evidence, targets, and medication-interaction planning. |
An indication is not a shortcut to eligibility. Diagnosis, body-mass criteria, previous care, current medicines, and contraindications still need review.
Understand what SURMOUNT-5 can and cannot tell you
SURMOUNT-5 followed 751 people for 72 weeks in a randomized comparison. Everyone had obesity, and diabetes was excluded. The study’s tolerated treatment ranges were 10 to 15 mg for tirzepatide and 1.7 to 2.4 mg for semaglutide. Average loss from starting weight reached 20.2 percent in the tirzepatide group versus 13.7 percent in the semaglutide group.
This was a direct comparison, which is more useful than placing separate trials side by side. Still, it reports averages for a selected population under trial conditions. It does not promise a result, describe every dose, establish long-term outcomes for every group, or decide whether side effects and access will make treatment sustainable. Keep the measured findings separate from the mechanistic explanations offered for them.
Before that appointment, published comparison pages can frame the trade-offs. LillyDirect describes the branded options, telehealth names such as Ro and Hims and Hers weigh the two drugs against their own catalogs, and HealthRX keeps a semaglutide vs tirzepatide guide that pairs the SURMOUNT-5 averages with the label cautions. A page like that is a preparation tool, not a stand-in for the prescriber weighing your chart.
Review medical history before comparing percentages
The strongest FDA warning on each label concerns thyroid C-cell tumors observed in animals. Neither medicine is an option for someone with MEN 2 or with medullary thyroid carcinoma in their own or family history. A prescriber should also ask about pregnancy plans, previous pancreatic or gallbladder problems, renal health, serious digestive symptoms, diabetic eye disease, glucose-lowering medicines, allergies, and procedures involving deep sedation or anesthesia.
Slower stomach emptying can change how orally taken drugs are handled. Zepbound has particular contraceptive instructions for people using oral hormonal methods around initiation and dose increases. Bring every prescription, over-the-counter product, and supplement to the review rather than assuming a weekly medicine has no interaction consequences.
Plan for tolerability and monitoring
Queasiness, loose stools, vomiting, constipation, and stomach discomfort appear frequently in the label data. SURMOUNT-5 reported mostly mild or moderate digestive events, clustered around the titration period. Population tolerability cannot predict one person’s experience.
Ask who handles persistent symptoms, which patterns need urgent assessment, and how the team responds to dehydration risk. Intense or unrelenting stomach pain, vomiting that prevents hydration, or a possible serious allergy should not wait for an ordinary check-in. Record symptoms with dates and doses so the pattern is legible at the next visit.
Test whether access is durable
A medicine that cannot be obtained consistently is not a practical long-term choice. Verify the exact product, presentation, pharmacy, prior authorization, deductible, copay, refill timing, and what happens if coverage changes. Manufacturer self-pay and savings programs can differ by dose and insurance status, and their terms can change.
Ask for the recurring cost after any introductory period. Include clinical visits, required laboratory work, supplies, and shipping. Do not assume the cheapest advertised amount covers an FDA-approved product or the full care plan. Prices in this category move quickly, so verify them on the decision date rather than inheriting a figure from an older article; services that post their full recurring price publicly, such as FormBlends, make that check faster than ones that reveal cost only after an intake.
Include administration and personal preference
Frequency is only one part of administration. Discuss device type, storage, travel, needle comfort, oral-medicine timing, and ability to follow the product instructions. Wegovy’s current labeling includes injection and tablet presentations, while Zepbound presentations and access channels have their own requirements. The oral field has also widened: orforglipron, approved in April 2026 under the brand name Foundayo, is a daily oral small-molecule GLP-1 agonist indicated for weight reduction and maintenance, and it is not approved for type 2 diabetes. Never treat two presentations as automatically interchangeable.
Preference matters because treatment is usually long term. A theoretically stronger average result has limited value if the plan is unacceptable, repeatedly interrupted, or poorly tolerated.
Ask what ongoing care looks like after the prescription. Clarify follow-up frequency, the route for questions between visits, who reviews adverse effects, and how treatment goals will be measured. A sales page that emphasizes fast enrollment but says little about reassessment provides an incomplete picture. Continuity includes clinical responsibility as well as product availability.
Nutrition, movement, sleep, and mental-health needs should also be considered without treating them as a moral test or a substitute for indicated care. A sustainable plan supports adequate nutrition and function while monitoring for unintended consequences such as excessive restriction or loss of lean mass.
Take this shortlist to the prescriber
- Which approved product and indication are we discussing?
- What personal factors favor one option?
- What factors make either option inappropriate?
- What benefit would be meaningful, and when will we reassess?
- What side effects should I report, and through which channel?
- Could this affect my oral medicines or contraception?
- What is the complete recurring cost and backup access plan?
- What is the plan if treatment is interrupted or changed?
A good answer should be specific to your chart. It should not rely on a social-media testimonial, a single percentage, or a sales-page quiz.
Frequently asked questions
Does greater average weight loss mean fewer side effects?
No. Efficacy and tolerability are separate questions. Review the adverse-event data and your own risk factors.
Should I choose based on the receptor mechanism?
No. Mechanism helps explain how a medicine works, but clinical outcomes, contraindications, tolerability, and access determine practical fit.
Can I change my mind after starting?
Yes, treatment can be reassessed. Do not stop, overlap, or switch on your own. Use a prescriber-led plan.
Is compounded semaglutide or tirzepatide equivalent?
No automatic equivalence should be assumed. Compounded drugs are not FDA approved and do not undergo the same premarket review.
Primary sources
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). PubMed: https://pubmed.ncbi.nlm.nih.gov/40353578/
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). PubMed: https://pubmed.ncbi.nlm.nih.gov/35658024/
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. PubMed: https://pubmed.ncbi.nlm.nih.gov/40960239/
- DailyMed, Zepbound prescribing information: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ZEPBOUND
- DailyMed, Wegovy prescribing information: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=WEGOVY
- FDA, Zepbound approval for obstructive sleep apnea: https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
- FDA, Wegovy approval for MASH: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
- FDA, compounding questions and answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
